CRISPR-Cas9–based target validation for p53-reactivating model compounds

Development and Applications of CRISPR-Cas9 for Genome Engineering

(2014) Patrick D. Hsu et al.   CELL

Limiting the power of p53 through the ubiquitin proteasome pathway

(2014) Vinod Pant et al.   GENES & DEVELOPMENT

DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells

(2014) Yegor Smurnyy et al.   Nature Chemical Biology

DrugTargetSeqR: a genomics- and CRISPR-Cas9–based method to analyze drug targets

(2014) Corynn Kasap et al.   Nature Chemical Biology

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays

(2014) Camilo Guzmán et al.   PLoS One

RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38

(2014) A Weilbacher et al.   Cell Death & Disease

Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases

(2014) Joël P. Charles et al.   Nature Communications

Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks

(2013) C. Shen et al.   CANCER RESEARCH

In vitro FANCD2 monoubiquitination by HHR6 and hRad18

(2013) Anna Pickering et al.   CELL CYCLE

Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro

(2013) M. Burmakin et al.   CLINICAL CANCER RESEARCH

mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells

(2013) F Guo et al.   LEUKEMIA

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Genome engineering using the CRISPR-Cas9 system

(2013) F Ann Ran et al.   Nature Protocols

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway

(2012) H. Kim et al.   GENES & DEVELOPMENT

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

A simple statistical test to infer the causality of target/phenotype correlation from small molecule phenotypic screens

(2011) Xin Wei et al.   BIOINFORMATICS

The E3 ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of FANCD2 and FANCI

(2011) S. A. Williams et al.   BLOOD

FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons

(2011) Lisa A. Kachnic et al.   CANCER LETTERS

3’UTR mediated regulation of the cyclin D1 proto-oncogene

(2011) Anagha Deshpande et al.   CELL CYCLE

Chk2 mediates RITA-induced apoptosis

(2011) J de Lange et al.   CELL DEATH AND DIFFERENTIATION

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease

FANCD2 monoubiquitination provides a link between the HHR6 and FA-BRCA pathways

(2010) Jun Zhang et al.   CELL CYCLE

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA

(2010) Carolyn Y. Zhao et al.   CELL CYCLE

Rad18-mediated Translesion Synthesis of Bulky DNA Adducts Is Coupled to Activation of the Fanconi Anemia DNA Repair Pathway

(2010) Ihn Young Song et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

DNA Binding Cooperativity of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis

(2010) Katharina Schlereth et al.   MOLECULAR CELL

Stage-specific sensitivity to p53 restoration during lung cancer progression

(2010) David M. Feldser et al.   NATURE

Translating p53 into the clinic

(2010) Chit Fang Cheok et al.   Nature Reviews Clinical Oncology

Convergence of Rad6/Rad18 and Fanconi Anemia Tumor Suppressor Pathways upon DNA Damage

(2010) Hwan Ki Park et al.   PLoS One

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis

(2009) Vera V. Grinkevich et al.   CANCER CELL

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

(2009) Martin Enge et al.   CANCER CELL

Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3

(2009) M. Michaelis et al.   CANCER RESEARCH

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

(2009) G. Bertolini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA